Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,985,922
  • Shares Outstanding, K 166,045
  • Annual Sales, $ 2,225 M
  • Annual Income, $ 272,000 K
  • 60-Month Beta 0.24
  • Price/Sales 2.75
  • Price/Cash Flow 13.65
  • Price/Book 3.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.40
  • Growth Rate Est. (year over year) +249,650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.05 unch
on 06/21/19
39.73 -9.26%
on 06/03/19
-1.97 (-5.18%)
since 05/21/19
3-Month
36.05 unch
on 06/21/19
42.82 -15.81%
on 05/07/19
-4.26 (-10.57%)
since 03/21/19
52-Week
29.00 +24.31%
on 07/19/18
42.82 -15.81%
on 05/07/19
+1.80 (+5.26%)
since 06/21/18

Most Recent Stories

More News
Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Phytonadione Injectable Emulsion USP,...

RDY : 36.05 (-2.09%)
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy's Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") announced positive topline results from its Phase 2b...

RDY : 36.05 (-2.09%)
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

RDY : 36.05 (-2.09%)
BMRN : 87.91 (+1.79%)
RGEN : 83.04 (-0.12%)
ACOR : 7.49 (+2.88%)
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the...

RDY : 36.05 (-2.09%)
New Strong Sell Stocks for May 22nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

BHLB : 29.99 (-1.45%)
CBT : 45.65 (-1.60%)
RDY : 36.05 (-2.09%)
CSFL : 22.60 (-1.09%)
TSG : 16.60 (-0.36%)
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

ANIK : 40.19 (-0.54%)
RDY : 36.05 (-2.09%)
AXGT : 6.86 (+18.48%)
AGTC : 3.80 (+0.53%)
Dr. Reddy's Q4 & FY19 Financial Results

Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International...

RDY : 36.05 (-2.09%)
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat

Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.

RDY : 36.05 (-2.09%)
Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Daptomycin for Injection,...

RDY : 36.05 (-2.09%)
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

RDY : 36.05 (-2.09%)
LOGC : 15.29 (+3.87%)
CTST : 5.09 (-2.30%)
BIIB : 239.09 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 37.18
1st Resistance Point 36.62
Last Price 36.05
1st Support Level 35.77
2nd Support Level 35.48

See More

52-Week High 42.82
Fibonacci 61.8% 37.54
Last Price 36.05
Fibonacci 50% 35.91
Fibonacci 38.2% 34.28
52-Week Low 29.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar